Vasculitis & polymyalgia rheumatica
EULAR recommendations for the management of Behçet’s syndrome: 2025 update
Methodological detailsEULAR update, Delphi survey, systematic literature review, levels of evidence and agreement, Task force of 29 members from 11 countries, including 2 patient research partners
- EULAR update
- Delphi survey
- Systematic literature review
- Levels of evidence and agreement
- Task force of 29 members from 11 countries, including 2 patient research partners
Recommendations
As issued by the authors
Overarching principles: recognise the relapsing and remitting disease course; individualise treatment according to disease activity and prognostic risk factors; multidisciplinary approach, patient education and shared decision making for optimal care
Mucocutaneous and joint involvement: colchicine is recommended as first-line treatment
Apremilast and immunosuppressives such as TNFα inhibitors are recommended for refractory patients
Organ involvement: more aggressive treatment with GC and immunosuppressives for rapid induction of remission
Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →